This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Dendreon's Date With Destiny

But the Provenge clinical data is understood to be really good. Didn't the drug improve survival in prostate cancer patients by 4½ months compared with men who got a placebo? I also understand the safety profile of Dendreon is exceptional.

Yes, that's correct. The survival benefit and its low toxicity are Provenge's biggest selling points and could very well persuade experts on the March 29 panel to recommend approval. But the reliability of that survival benefit isn't crystal-clear.

Huh? There's nothing clearer than survival in a cancer study. A patient is alive or dead, correct?

True, but the Provenge phase III trial was designed to measure time-to-disease progression -- not survival -- as its primary endpoint. And on this score, the trial was a statistical failure. The measurement of survival was a secondary efficacy endpoint in the study, so while it was statistically significant, the validity of this finding is not a slam dunk.

Even the authors of the Provenge clinical study, published last year in the Journal of Clinical Oncology, take a cautious approach:

"While overall survival at 36 months was prespecified in the analysis plan, it was not specified as the primary efficacy end point, so the P value obtained for this analysis should be interpreted with caution," the authors wrote. A P value is a statistical measure of confidence that an outcome is the result of treatment, and not random chance.

This is old news. Dendreon did its own analysis to confirm Provenge's survival benefit, correct?

Indeed, and much of what Dendreon did is pretty convincing. For instance, skeptics had long thought that there were imbalances and other factors between the two arms of the Provenge study that favored the drug over placebo. This would explain why Provenge patients lived longer, skeptics believed.

But when researchers crunched the numbers, the truth was actually reversed. There were few imbalances in the study's two arms, and in fact, there were several factors that actually worked against Provenge.

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs